Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.

Abstract

BACKGROUND AND AIMS:

Paradoxically, psoriasis or psoriasiform skin lesions induced or exacerbated by anti-TNF antibodies have been described. Here, we report a series of 13 novel cases featuring exacerbation or occurrence of psoriatic skin lesions induced by anti-TNF antibodies in patients with Crohn's disease (CD).

METHODS:

We performed a systematic analysis of exacerbation or occurrence of psoriasis or psoriasiform skin lesions induced by anti-TNF antibodies in an inflammatory bowel disease patient cohort at the University Hospital Zurich.

RESULTS:

We identified 13 CD patients who developed psoriasis or psoriasiform lesions while receiving anti-TNF therapy. 10 of the 13 patients were female with an average age of 26.9 years at diagnosis. 11 of the 13 patients had a complicated disease. The mean time of clinical latency between diagnosis and onset of psoriasis was about 9.4 years, and the time between the beginning of all biological infusions and the onset of psoriasis was about 7 months. 7 of the 13 patients received infliximab, 3 adalimumab, and 3 certolizumab pegol at onset of psoriasis. In most of the cases, anti-TNF therapy was changed or discontinued and skin lesions improved.

CONCLUSION:

Most of our described patients featured a complicated disease course of CD and had an improvement of the rash after changing the anti-TNF therapy.

• Authors: Christiane Barthel, Luc Biedermann, Pascal Frei, Stephan R Vavricka, Thomas Kündig, Michael Fried, Gerhard Rogler, Michael Scharl
• Journal: Digestion (Digestion) Vol. 89 Issue 3 Pg. 209-15 ( 2014) ISSN: 1421-9867 [Electronic] Switzerland
• PMID: 24853251 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Immunoglobulin Fab Fragments
• Immunosuppressive Agents
• Tumor Necrosis Factor-alpha
• Polyethylene Glycols
• golimumab
• Adalimumab
• Certolizumab Pegol

Topics

• Adalimumab
• Adolescent
• Adult
• Anti-Inflammatory Agents (adverse effects, therapeutic use)
• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Certolizumab Pegol
• Crohn Disease
• Disease Progression
• Female
• Humans
• Immunoglobulin Fab Fragments (therapeutic use)
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Male
• Middle Aged
• Polyethylene Glycols (therapeutic use)
• Psoriasis (chemically induced, immunology)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)
• Young Adult